Abstract:The serine-threonine kinase, tumor progression locus 2 (Tpl2, also known as Map3k8/Cot), is a potent inflammatory mediator that drives the production of TNFα, IL-1β, and IFNγ. We previously demonstrated that Tpl2 regulates TCR signaling and modulates T helper cell differentiation. However, very little is known about how Tpl2 modulates the development of regulatory T cells (Tregs). Tregs are a specialized subset of T cells that express FoxP3 and possess immunosuppressive properties to limit excess inflammation. Because of the documented role of Tpl2 in promoting inflammation, we hypothesized that Tpl2 antagonizes Treg development and immunosuppressive function. Herein, we demonstrate that Tpl2 constrains the development of inducible Tregs (iTregs). Tpl2 naïve CD4 T cells preferentially develop into FoxP3 iTregs in vitro as well as in vivo in a murine model of OVAinduced systemic tolerance. Treg biasing of Tpl2 T cells depended upon the TCR signal strength and corresponded with reduced activation of the mammalian target of rapamycin (mTOR) pathway. Importantly, Tpl2 Tregs have basally increased expression of FoxP3 and immunosuppressive molecules, IL-10 and cytotoxic T lymphocyteassociated protein 4 (CTLA-4). Furthermore, they were more immunosuppressive in vivo in a T cell transfer model of colitis, as evidenced by reducing effector T cell accumulation, systemic production of inflammatory cytokines, and colonic inflammation. These results demonstrate that Tpl2 promotes inflammation in part by constraining FoxP3 expression and Treg immunosuppressive functions. Overall these findings suggest that Tpl2 inhibition could be used to preferentially drive Treg induction and thereby limit inflammation in a variety of autoimmune diseases. INTRODUCTION Pathogenesis of a number of autoimmune diseases is attributed to self-reactive T cells that recognize self-antigens and trigger organ-specific damage (1). Regulatory T cells are a specialized lineage of T cells with immunosuppressive properties. The forkhead box P3 (FoxP3) transcription factor is important in specifying this lineage (2,3), and humans with mutations in the Foxp3 gene develop severe multi-organ autoimmune disease including autoimmune enteropathy, dermatitis, thyroiditis, and type I diabetes (4). This syndrome is highly homologous to that observed in scurfy mice that also harbor mutations within the Foxp3 gene (5). Tregs arise naturally in the thymus (natural Tregs, nTregs or thymus-derived Tregs, tTregs) or can be induced from naïve conventional T cells in the periphery (inducible Tregs; iTregs) (6-9). Both types of FoxP3 Tregs exhibit critical immunoregulatory functions to maintain central and peripheral http://www.jbc.org/cgi/doi/10.1074/jbc.M116.718783 The latest version is at JBC Papers in Press. Published on June 3, 2016 as Manuscript M116.718783 Copyright 2016 by The American Society for Biochemistry and Molecular Biology, Inc. by gest on N ovem er 8, 2017 hp://w w w .jb.org/ D ow nladed from

mTORC1 inhibition promotes human Treg differentiation via privileged mRNA translation

A DAP5/eIF3d alternate mRNA translation mechanism promotes differentiation and immune suppression by human regulatory T cells

Induced miR‐99a expression represses Mtor cooperatively with miR‐150 to promote regulatory T‐cell differentiation

Nutrient Mtorc1 Signaling Underpins Regulatory T Cell Control of Immune Tolerance

A Cellular MicroRNA Facilitates Regulatory T Lymphocyte Development by Targeting the FOXP3 Promoter TATA-Box Motif.

Interplay Between Mtor and STAT5 Signaling Modulates the Balance Between Regulatory and Effective T Cells.

mTOR signaling promotes cytokine production in T cells through 3UTR-mediated translation control

Rapamycin Promotes Expansion of Cd4+Cd25+Foxp3+Regulatory T Cells by Modulating Fatty Acid Metabolism?

Tumor progression locus 2 ( Tpl 2 ) activates the mTOR pathway , inhibits FoxP 3 expression and limits Treg immunosuppressive functions

TGF-β1 Maintains Foxp3 Expression and Inhibits Glycolysis in Natural Regulatory T Cells Via PP2A-mediated Suppression of Mtor Signaling.

Metabolic Disruption Induced by mTOR Signaling Pathway Inhibition in Regulatory T-Cell Expansion for Clinical Application

Tumor Progression Locus 2 (tpl2) Activates the Mammalian Target of Rapamycin (mtor) Pathway, Inhibits Forkhead Box P3 (foxp3) Expression, and Limits Regulatory T Cell (treg) Immunosuppressive Functions

Functional reprogramming of regulatory T cells in the absence of Foxp3

Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3

TGF-β Induces Foxp3 + T-Regulatory Cells from CD4 + CD25 − Precursors

Roles of Mtorc1 and Mtorc2 in Controlling Γδ T1 and Γδ T17 Differentiation and Function

Rapamycin together with TGF-β1, IL-2 and IL-15 induces the generation of functional regulatory γδT cells from human peripheral blood mononuclear cells.

TGFβ limits Myc-dependent TCR-induced metabolic reprogramming in CD8+ T cells

T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR

Reciprocal regulation of mTORC1 signaling and ribosomal biosynthesis determines cell cycle progression in activated T cells

Noc4L-Mediated Ribosome Biogenesis Controls Activation of Regulatory and Conventional T Cells.